

Pursuant to the provisions of article 228 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. hereby informs about the following

RELEVANT EVENT

Grifols, S.A. ("**Grifols**"), through its subsidiary Grifols Shared Services North America, Inc. has completed the acquisition of 100% of the shares in Biotest US Corporation ("**Biotest USA**") for a price of USD 286M, after obtaining the consent of the Federal Trade Commission. The shares have been acquired from Biotest Divestiture Trust.

Biotest USA owns a plasma collection business in the USA with 24 plasma collection centers throughout the territory. In the preceding financial year, they have obtained approximately 850,000 liters of plasma.

In Barcelona, on 1 August 2018

Nuria Martín Barnés
Secretary to the Board of Directors